ArticleAntimicrobial agents and chemotherapy2015
Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06266494 (Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis), which is not on this map. Cited by 125 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis
Who cites it
125 citing papers in PubMed, 226 citations in OpenAlex.
- Simulated Target Attainment of Multidose Regimens of Dalbavancin for Prolonged Durations of Therapy.Open forum infectious diseases · 2024Trial
- Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis.Open forum infectious diseases · 2024Trial
- Effective use of a two-dose regimen of dalbavancin to treat prosthetic joint infections and spinal hardware infections.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2023Trial
- Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis.Clinical pharmacology in drug development · 2020Trial
- Effects of Sub-Inhibitory Rifampicin, Minocycline, and Dalbavancin on Early Biofilm Formation and Transcriptional Responses inMicroorganisms · 2026Article
- Review
- Methicillin-resistant Staphylococcus aureus.Nature reviews. Disease primers · 2026Review
- Population pharmacokinetics of dalbavancin: external validation, model averaging, and implications for precision dosing in prolonged therapy.Antimicrobial agents and chemotherapy · 2026Article
- A real-world implementation study of a TDM-guided dalbavancin model for bone and joint infections (101 Dalbatians).JAC-antimicrobial resistance · 2026Article
- Real-World Effectiveness of Dalbavancin in Osteomyelitis Without Implantable Devices: A Retrospective Monocentric Study.Antibiotics (Basel, Switzerland) · 2026Article
- Off-label use of dalbavancin to improve treatment outcomes and reduce health care costs in people who use drugs: A Canadian single-centre quality improvement initiative.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2026Article
- Septic Arthritis of the Pubic Symphysis in an Adolescent Athlete: A Rare and Atypical Presentation.Cureus · 2026Article
- TDM-Guided Dalbavancin Treatment for ComplexAntibiotics (Basel, Switzerland) · 2026Article
- Methicillin-resistant and susceptible Staphylococcus aureus: tolerance, immune evasion and treatment.Nature reviews. Microbiology · 2026Review
- Case Series: Use of Dalbavancin for Invasive Gram-Positive Infection in Children.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Real world use of dalbavancin for bone and joint infections: a retrospective case series in adults and children.BMC research notes · 2026Article
- Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?The Journal of antimicrobial chemotherapy · 2026Article
- Predicting prolonged dalbavancin exposure using machine learning: a validated strategy for individualized redosing.Antimicrobial agents and chemotherapy · 2026Article
- Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin for short-term therapy in patients with chronic prosthetic joint infections.Antimicrobial agents and chemotherapy · 2025Observational
- Budget Impact and Financial Analysis of Outpatient Dalbavancin in an Urban, Non-Teaching, Community Hospital.Clinical drug investigation · 2025Article
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dalbavancin is an intravenous lipoglycopeptide with activity against Gram-positive pathogens and an MIC90 for Staphylococcus aureus of 0.06 μg/ml. With a terminal half-life of >14 days, dosing regimens with infrequent parenteral administration become available to treat infectious diseases such as osteomyelitis and endocarditis that otherwise require daily dosing for many weeks. In order to support a rationale for these novel regimens, the pharmacokinetics over an extended dosing interval and the distribution of dalbavancin into bone and articular tissue were studied in two phase I trials and pharmacokinetic modeling was performed. Intravenous administration of 1,000 mg of dalbavancin on day 1 followed by 500 mg weekly for seven additional weeks was well tolerated and did not demonstrate evidence of drug accumulation. In a separate study, dalbavancin concentrations in cortical bone 12 h after infusion of a single 1,000-mg intravenous infusion were 6.3 μg/g and 2 weeks later were 4.1 μg/g. A two-dose, once-weekly regimen that would provide tissue exposure over the dalbavancin MIC for Staphylococcus aureus for 8 weeks, maximizing the initial exposure to treatment while minimizing the frequency of intravenous therapy, is proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.